Japāna - angļu - すりの適正使用協議会 RAD-AR Council, Japan

sun pharma japan limited - ciclosporin - yellowish white capsule, major axis: 18.1 mm, minor axis: 6.4 mm

Malta - angļu - Medicines Authority

medicem limited 57a ta’ maggi industrial estate, st. leonard street, xghajra l/o zabbar, zbr 2305, malta - ciclosporin - soft capsule - ciclosporin 50 mg - immunosuppressants

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

viatris limited - fluconazole 150mg; fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 titanium dioxide active: fluconazole 150mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate maize starch sodium laurilsulfate tekprint black sw-9008 titanium dioxide - 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant 6. fluconazole 50 mg & 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

viatris limited - fluconazole 50mg; fluconazole 50mg; fluconazole 50mg - capsule - 50 mg - active: fluconazole 50mg excipient: erythrosine gelatin hydrated silica lactose monohydrate magnesium stearate patent blue v pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide active: fluconazole 50mg excipient: erythrosine gelatin hydrated silica lactose monohydrate magnesium stearate maize starch patent blue v sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide active: fluconazole 50mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate maize starch patent blue v ponceau 4r sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide - 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant 6. fluconazole 50 mg & 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: ammonia solution butyl alcohol colloidal silicon dioxide ethanol gelatin   iron oxide black isopropyl alcohol lactose monohydrate magnesium stearate maize starch patent blue v   potassium hydroxide propylene glycol purified water   shellac sodium laurilsulfate titanium dioxide   water - ozole 150 mg capsule, given orally, is indicated for vaginal candidiasis.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fluconazole 50mg - capsule - 50 mg - active: fluconazole 50mg excipient: ammonia solution butyl alcohol colloidal silicon dioxide ethanol gelatin   iron oxide black isopropyl alcohol lactose monohydrate magnesium stearate maize starch patent blue v potassium hydroxide propylene glycol purified water   shellac sodium laurilsulfate titanium dioxide   water - ozole is indicated for the treatment of the following conditions: 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. ozole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseninated candidasis and other forms of invasive candidal infection, including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytoxic chemotherapy, radiotherapy or bone marrow transplant. 6. ozole 50 mg and 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.

Īrija - angļu - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - ciclosporin - capsules, soft - 25 milligram

Īrija - angļu - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - ciclosporin - capsules, soft - 50 milligram

Īrija - angļu - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - ciclosporin - capsules, soft - 100 milligram

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - ciclosporin - oral capsule - 25mg